Amarillo Biosciences is a specialty biopharmaceutical company working in Phase 2 human clinical trials with a characterized therapeutic agent, low-dose interferon alpha, in a proprietary oral formulation. The interferon-alpha in their oral product is produced naturally from human cells, making it superior to high-dose injectable interferon, which is made in bacteria or yeast by recombinant technology. Their low-dose oral interferon has been shown to have fetheyr side effects and is less costly than high-dose injectable interferon. They have license to low-dose oral interferon from Texas A&M University and agreements in place with their international partner companies who are pursuing clinical trials globally. Their management team and corporate partners are working to develop a non-toxic and inexpensive low-dose oral formulation of interferon-alpha for the benefit of patients and physicians worldwide. Amarillo Biosciences and its partners are pursuing major disease indications with a focus on influenza and hepatitis C.